EX-10.14 7 filename7.htm CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN...Distribution and Sublicense Agreement • May 5th, 2020 • New York
THIS DISTRIBUTION AND SUBLICENSE AGREEMENT (this “Agreement”), dated as of February 1, 2016 (the “Effective Date”), by and between BRAEBURN PHARMACEUTICALS, INC., a corporation formed under the laws of Delaware (“Braeburn”), and KNIGHT THERAPEUTICS INC., a corporation incorporated under the laws of Canada (“Knight”).
EXECUTION VERSION CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[*******]” OR OTHERWISE CLEARLY INDICATED. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO...Distribution and Sublicense Agreement • May 5th, 2020 • New York
THIS DISTRIBUTION AND SUBLICENSE AGREEMENT (this “Agreement”), dated as of February 1, 2016 (the “Effective Date”), by and between Braeburn Pharmaceuticals, inc., a corporation formed under the laws of Delaware (“Braeburn”), and Knight Therapeutics Inc., a corporation incorporated under the laws of Canada (“Knight”).
EXHIBIT 10.22 DISTRIBUTION AND SUBLICENSE AGREEMENT THIS TERRITORIAL DISTRIBUTION AND SUBLICENSE AGREEMENT (the "AGREEMENT"), is entered into as of the 1st day of December, 2004 (the "EFFECTIVE DATE"), by and between Alfred Hanser, an adult individual...Distribution and Sublicense Agreement • April 4th, 2005 • Fem One Inc • Medicinal chemicals & botanical products • California
